COVID-19后甲状腺疾病的表现:桥本甲状腺炎、Graves病和亚急性甲状腺炎报告

Q4 Medicine
Karen Feghali, Jacqueline Atallah, Catalina Norman
{"title":"COVID-19后甲状腺疾病的表现:桥本甲状腺炎、Graves病和亚急性甲状腺炎报告","authors":"Karen Feghali,&nbsp;Jacqueline Atallah,&nbsp;Catalina Norman","doi":"10.1016/j.jecr.2021.100094","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>We present three cases of thyroid dysfunction such as Hashimoto thyroiditis, Graves’ disease and subacute thyroiditis which developed few weeks after resolution of acute phase of COVID -19 infection in patients with no prior thyroid disease.</p></div><div><h3>Methods</h3><p>We discuss clinical presentation, diagnostic evaluation and subsequent management and follow-up in three patients.</p></div><div><h3>Results</h3><p>All three patients tested positive for COVID-19 infection prior to diagnosis. Patient 1. A 38-year-old female developed hypothyroidism 6 weeks after COVID-19 infection, confirmed by TSH 136 mIU/L (range 0.34–5.6), free T4 level 0.2 ng/dL (range 0.93–1.7). Patient 2. A 33-year-old female developed Graves’ disease 8 weeks after COVID-19 infection, with a TSH &lt;0.01 mIU/L (range 0.4–4.5), Free T4 2.1 ng/dl (range 0.8–1.8), total T3 216 ng/dl (range 76–181), elevated TSI 309 (normal &lt;140). A 24-h thyroid uptake was calculated at 47.1% (normal values between 8% and 35). Patient responded favorably to methimazole 10 mg in few weeks. Patient 3. A 41-year old healthy female developed thyroiditis at 6 weeks after COVID-19 infection, with a TSH 0.01 mIU/L and free T4 1.9 ng/dL accompanied by low 24-h thyroid uptake, calculated at 0.09%. Three weeks later, she developed hypothyroidism, with a TSH 67.04 mIU/L and free T4 0.4 ng/dl.</p></div><div><h3>Conclusion</h3><p>The temporal relationship between COVID-19 infection in the patients described here raises the question of possible effects of COVID-19 on the immune system and the thyroid gland.</p></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"22 ","pages":"Article 100094"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jecr.2021.100094","citationCount":"45","resultStr":"{\"title\":\"Manifestations of thyroid disease post COVID-19 illness: Report of Hashimoto thyroiditis, Graves’ disease, and subacute thyroiditis\",\"authors\":\"Karen Feghali,&nbsp;Jacqueline Atallah,&nbsp;Catalina Norman\",\"doi\":\"10.1016/j.jecr.2021.100094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>We present three cases of thyroid dysfunction such as Hashimoto thyroiditis, Graves’ disease and subacute thyroiditis which developed few weeks after resolution of acute phase of COVID -19 infection in patients with no prior thyroid disease.</p></div><div><h3>Methods</h3><p>We discuss clinical presentation, diagnostic evaluation and subsequent management and follow-up in three patients.</p></div><div><h3>Results</h3><p>All three patients tested positive for COVID-19 infection prior to diagnosis. Patient 1. A 38-year-old female developed hypothyroidism 6 weeks after COVID-19 infection, confirmed by TSH 136 mIU/L (range 0.34–5.6), free T4 level 0.2 ng/dL (range 0.93–1.7). Patient 2. A 33-year-old female developed Graves’ disease 8 weeks after COVID-19 infection, with a TSH &lt;0.01 mIU/L (range 0.4–4.5), Free T4 2.1 ng/dl (range 0.8–1.8), total T3 216 ng/dl (range 76–181), elevated TSI 309 (normal &lt;140). A 24-h thyroid uptake was calculated at 47.1% (normal values between 8% and 35). Patient responded favorably to methimazole 10 mg in few weeks. Patient 3. A 41-year old healthy female developed thyroiditis at 6 weeks after COVID-19 infection, with a TSH 0.01 mIU/L and free T4 1.9 ng/dL accompanied by low 24-h thyroid uptake, calculated at 0.09%. Three weeks later, she developed hypothyroidism, with a TSH 67.04 mIU/L and free T4 0.4 ng/dl.</p></div><div><h3>Conclusion</h3><p>The temporal relationship between COVID-19 infection in the patients described here raises the question of possible effects of COVID-19 on the immune system and the thyroid gland.</p></div>\",\"PeriodicalId\":56186,\"journal\":{\"name\":\"Journal of Clinical and Translational Endocrinology: Case Reports\",\"volume\":\"22 \",\"pages\":\"Article 100094\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jecr.2021.100094\",\"citationCount\":\"45\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical and Translational Endocrinology: Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2214624521000174\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology: Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214624521000174","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 45

摘要

目的报告3例无甲状腺疾病的新型冠状病毒感染急性期消退数周后出现桥本甲状腺炎、Graves病和亚急性甲状腺炎的病例。方法对3例患者的临床表现、诊断评价、后续处理及随访进行分析。结果3例患者诊断前COVID-19感染检测均为阳性。患者1。38岁女性,感染新冠病毒6周后出现甲状腺功能减退,TSH 136 mIU/L(范围0.34-5.6),游离T4水平0.2 ng/dL(范围0.93-1.7)。病人2。33岁女性,感染新冠病毒8周后出现Graves病,TSH 0.01 mIU/L(范围0.4-4.5),游离T4 2.1 ng/dl(范围0.8-1.8),总T3 216 ng/dl(范围76-181),TSI升高309(正常140)。24小时甲状腺摄取为47.1%(正常值为8% ~ 35%)。患者在几周内服用甲巯咪唑10mg后反应良好。患者3。41岁健康女性感染新冠病毒后6周发生甲状腺炎,TSH 0.01 mIU/L,游离T4 1.9 ng/dL, 24 h甲状腺摄取低,计算为0.09%。3周后,患者出现甲状腺功能减退,TSH 67.04 mIU/L,游离T4 0.4 ng/dl。结论本文所述患者COVID-19感染的时间关系提出了COVID-19可能对免疫系统和甲状腺产生影响的问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Manifestations of thyroid disease post COVID-19 illness: Report of Hashimoto thyroiditis, Graves’ disease, and subacute thyroiditis

Objective

We present three cases of thyroid dysfunction such as Hashimoto thyroiditis, Graves’ disease and subacute thyroiditis which developed few weeks after resolution of acute phase of COVID -19 infection in patients with no prior thyroid disease.

Methods

We discuss clinical presentation, diagnostic evaluation and subsequent management and follow-up in three patients.

Results

All three patients tested positive for COVID-19 infection prior to diagnosis. Patient 1. A 38-year-old female developed hypothyroidism 6 weeks after COVID-19 infection, confirmed by TSH 136 mIU/L (range 0.34–5.6), free T4 level 0.2 ng/dL (range 0.93–1.7). Patient 2. A 33-year-old female developed Graves’ disease 8 weeks after COVID-19 infection, with a TSH <0.01 mIU/L (range 0.4–4.5), Free T4 2.1 ng/dl (range 0.8–1.8), total T3 216 ng/dl (range 76–181), elevated TSI 309 (normal <140). A 24-h thyroid uptake was calculated at 47.1% (normal values between 8% and 35). Patient responded favorably to methimazole 10 mg in few weeks. Patient 3. A 41-year old healthy female developed thyroiditis at 6 weeks after COVID-19 infection, with a TSH 0.01 mIU/L and free T4 1.9 ng/dL accompanied by low 24-h thyroid uptake, calculated at 0.09%. Three weeks later, she developed hypothyroidism, with a TSH 67.04 mIU/L and free T4 0.4 ng/dl.

Conclusion

The temporal relationship between COVID-19 infection in the patients described here raises the question of possible effects of COVID-19 on the immune system and the thyroid gland.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Clinical and Translational Endocrinology: Case Reports
Journal of Clinical and Translational Endocrinology: Case Reports Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
1.10
自引率
0.00%
发文量
32
审稿时长
27 weeks
期刊介绍: The journal publishes case reports in a variety of disciplines in endocrinology, including diabetes, metabolic bone disease and osteoporosis, thyroid disease, pituitary and lipid disorders. Journal of Clinical & Translational Endocrinology Case Reports is an open access publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信